Navigation Links
Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform
Date:2/14/2013

BUDAPEST, Hungary & BOSTON, February 14, 2013 /PRNewswire/ --

Leading pharmaceutical company continues the trend of building future cheminformatics platforms on ChemAxon technology

ChemAxon, a leader in providing chemistry software solutions and consulting services for life science research, announces that Boehringer Ingelheim has chosen its chemistry software platform for multiple applications across research and development, supporting in-house activities and work with external collaboration partners. ChemAxon technology will be used to store, search, calculate, and visualize chemical entities, properties and reactions, helping to streamline the progression from drug discovery to clinical candidate.  ChemAxon was chosen after an extensive evaluation process that built on dimensions such as ROI, performance, robustness, scalability and future development roadmap.

ChemAxon sets the standard in chemically-intelligent software for pharmaceutical R&D. With a client list that includes all of the top 15 global pharma companies, the company continues to experience significant growth year on year.

Commenting on the agreement, Alex Drijver, CEO of ChemAxon said, "The adoption of ChemAxon technology by Boehringer Ingelheim further underlines our position as the platform of choice for R&D organizations planning their next-generation systems."  

To discover more about how ChemAxon's leading edge cross-platform solutions power modern cheminformatics and chemical communication, please visit http://www.chemaxon.com

About ChemAxon
ChemAxon is a leader in providing cheminformatics software platforms and desktop applications for the biotechnology, pharmaceutical and agrochemical industries. With core capabilities for structure visualization, search and management, property prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon active interaction with users and software portability to create powerful, cost effective cross platform solutions that power modern cheminformatics and chemical communication. The company is privately owned with European headquarters in Budapest, US East Coast headquarters in Cambridge, MA, and sales and support offices in Europe, Japan and across North America.


'/>"/>
SOURCE ChemAxon Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , Feb. 9, 2016 The life of ... Medical Center, has been anything but ordinary.  Twists of fate, ... World War II and the constraints of communist Czechoslovakia to ... there, he would go on to make history by playing ... three best-selling drugs in the world, Remicade.  Dr. Vilcek brings ...
(Date:2/9/2016)... Feb. 9, 2016  Bluestar Silicones will promote its ... for long-term implant applications and announce certification of ... Manufacturing (MD&M) West Conference (Booth #1759), February 9-10, ... --> --> Available in 01 ... offer outstanding physical properties enabling our customers to ...
(Date:2/8/2016)... Cardiovascular Surgery Devices - Medical Devices ... Devices sector report, "Cardiovascular Surgery Devices - Medical ... Cardiovascular Surgery Devices currently in pipeline stage. ... report provides comprehensive information on the pipeline products ... stages of development. The report reviews major players ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with substantially ... to make a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... TopConsumerReviews.com recently ... in Mole removal products. , Moles are derived from a cluster of melanin when ... all the wrong places and create a lifetime of embarrassment. Historically, mole removal ...
(Date:2/8/2016)... ... 08, 2016 , ... Guruji Mahendra Kumar Trivedi is offering 3 days of ... of his birthday on February 10th. During this time, people can achieve better ... over 250,000 people from over 40 different countries as an “ordinary man with an ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to research by the ... dental technicians to be certified or obtain continuing education. To increase patient awareness ... In Your Mouth?” campaign to inform dentists and patients about the possible lack ...
(Date:2/7/2016)... ... February 07, 2016 , ... Women's Excellence staff, in all four locations, ... National Wear Red Day is the first Friday each February and a day to ... 1 in 3 deaths among women each year – more than all cancers combined. ...
Breaking Medicine News(10 mins):